
Please try another search
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and regulatory support services; and quality, biosafety and analytical testing services, as well as manufactures drug substance. In addition, it engages in the development and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Name | Age | Since | Title |
---|---|---|---|
John Chongbo Rim | 64 | 2019 | CEO, President & Chairman of Board |
Ho Seung Lee | - | 2025 | Independent Director |
Kun Lo | 62 | 2023 | Executive VP, Head of EPCV Center & Director |
Seoung Hwan Suh | 69 | 2024 | Independent Director |
Changwoo Lee | 56 | - | Independent Director |
Geunnyeong Heo | 69 | 2019 | Independent Director |
Kyonghee Kim | 66 | 2020 | Independent Outside Director |
Seung ho Ryu | - | 2024 | EVP, CFO, Head of Business Support Center & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review